Daily Archives: April 23, 2017

پنجره دو سه جداره

رکره بين شيشه دوجداره ,شرکت ماندگار سازنده در و پنجره دوجداره upvc, پنجره دوجداره وينتک , پنجره يو پي وي سي ويستابست, پنجره يو پي وي سي کشويي وينتک , پرده
یک درب و پنجره دوجداره خوب بایستی پاسخ گوی نیازهای ما بوده و بعنوان یک عایق حرارتی مناسب ، موجب از دست رفتن کمترین میزان انرژی ، جهت دستیابی به شيشه دوجداره طرح دار یا دکوراتيو جورجين بار از انواع شيشه هاي تزييني مي باشد که در نماي ساختمان و معماري داخلي مورد استفاده قرار مي گيرد و بر روي تمامي درب و پنجره هاي دوجداره UPVC، آلومنيومي، آهني و چوبي قابل جايگذاري مي باشد.تهویه مطبوع هوای داخل ساختمان گردد

Alzheimer

Todo lo que debe saber sobre su memoria y co´mo entrenarla


No one likes to imagine that they will put their beloved a person within a nursing house a person day. Regretably, most Alzheimer’s individuals ultimately will need to generally be positioned within an Alzheimer’s care facility. Because Alzheimer’s disease robs anyone of his / her capacity to take care of everyday things to do, frequently households will discover they cannot care for their beloved 1 in the home. It can be normally during the later phases from the ailment when individuals get rid of their capacity to manage costume them selves, feed themselves and want help going to the rest room that an Alzheimer’s treatment facility is taken into account by families. Find More Info Alzheimer

Mapi Pharma Ltd (MAPI) – Pharmaceuticals & Healthcare – with comprehensive analysis.  

 

HTF Market Intelligence released a new research report of 21 pages on title ‘Mapi Pharma Ltd (MAPI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile’  with detailed analysis, forecast and strategies.

Summary

Lakewood-Amedex Inc – Pharmaceuticals & Healthcare – outlook by HTF.  

 

HTF Market Intelligence released a new research report of 16 pages on title ‘Lakewood-Amedex Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile’  with detailed analysis, forecast and strategies.

Summary

Lakewood-Amedex Inc (Lakewood-Amedex) is a clinical stage biopharmaceutical company that focuses on the development of anti-infective pharmaceuticals. The company develops anti-infective products, including anti-bacterial compounds, gene-silencing anti-virals, locally delivered and orally available nanoRNA therapeutics. Lakewood Amedex produces nRNA therapeutics for the treatment of infectious diseases including hepatitis B, influenza, hepatitis C, and nasopharyngeal carcinoma induced by Epstein Barr virus. Lakewood-Amedex‘s lead product candidate includes Nu-3, which is being developed for the treatment of complicated diabetic foot ulcers. The company works in partnership with other biopharmaceutical companies, animal health companies, and academic and government institutions to develop and commercialize its products. Lakewood-Amedex is headquartered in Sarasota, Florida, the US.

Admedus Ltd (AHZ) – Pharmaceuticals & Healthcare – business overview and scope.

 

HTF Market Intelligence released a new research report of 31 pages on title ‘Admedus Ltd (AHZ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile’  with detailed analysis, forecast and strategies.

Summary

Admedus Ltd (Admedus) formerly Allied Healthcare Group Ltd, is a healthcare company that develops, manufactures and distributes medical devices and technologies with focus on tissue engineering and immunotherapies. Its flagship product, CardioCel is a regenerative tissue for cardiac repairs and reconstructions. The company also distributes infusion systems including ambulatory pumps, syringe and volumetric pumps, administration accessories, Amnicot finger cot, nasal spray (PCA) device and O’Neil urinary catheters. Admedus is developing next generation vaccines for the treatment and prevention of infectious diseases and cancers with an initial focus on Herpes Simplex Virus (HSV-2) and Human papillomavirus (HPV). It company has a state-of-the-art manufacturing facility in Malaga. The company offers its products to healthcare facilities in North America, Europe and Asia. Admedus is headquartered in Malaga, Western Australia.

Allergan Plc (AGN) – Pharmaceuticals & Healthcare – market industry perspective and comprehensive analysis.  

 

HTF Market Intelligence released a new research report of 267 pages on title ‘Allergan Plc (AGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile’  with detailed analysis, forecast and strategies.

Summary

Allergan Plc (Allergan), formerly Actavis plc is a specialty pharmaceutical company, which focuses on the development, manufacturing, marketing and distribution of specialty branded, bio-similar, and over-the-counter (OTC) products. It offers products in the areas of ophthalmology, neurosciences and medical aesthetics, dermatology, plastic surgery, central nervous system, gastroenterology, women’s health and urology. The company distributes branded pharmaceutical products of its own and third parties through its ANDA Distribution business to independent pharmacies, pharmacy buying groups, pharmacy chains and physicians’ offices. It has operations in several countries across the world including the US, Canada, China, India, and other high growth markets in Europe, Southeast Asia, Middle East and Latin America. Allergan is headquartered in Dublin, Ireland.

MitoGenetics LLC – Pharmaceuticals & Healthcare with detailed  analysis and forecast.  

 

HTF Market Intelligence released a new research report of 16 pages on title ‘MitoGenetics LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile’  with detailed analysis, forecast and strategies.

Summary

MitoGenetics LLC (MitoGenetics) is a biomedical research and development company which produces proprietary compounds and intellectual property for the treatment of human, animal and plant diseases caused due to mitochondrial dysfunction. The company offers technology to regulate cellular mitochondria. Its patent portfolio encompasses a number of provisional or pending patents for various disorders such as morphine precursor and related patents for morphine insufficiency syndrome. MitoGenetics focuses its research activities on therapeutic interventions that affect mitochondrial performance and restore its normal function in disorders. The company licenses its technology to other companies and academic institutions to advance development of its compounds. It operates laboratory in Sioux Falls, South Dakota, the US. MitoGenetics is headquartered in Farmingdale, New York, the US.

Mitobridge Inc – Pharmaceuticals & Healthcare – market status and trends.  

 

HTF Market Intelligence released a new research report of 16 pages on title ‘Mitobridge Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile’  with detailed analysis, forecast and strategies.

Summary

Mitobridge Inc (Mitobridge), formerly Mitokyne, Inc., is a biopharmaceutical company that discovers and develops small molecule therapeutics for the treatment of diseases with high unmet medical need. It provides products that enhance the mitochondrial functions. Mitobridge primarily focuses on developing therapies for rare diseases and then expand into more common diseases. It utilizes screening platform to identify and develop novel therapeutics. The company holds expertise in the areas of mitochondrial genetic diseases, musculoskeletal, kidney and neurodegenerative disorders as well as diseases and conditions of aging. It works in collaboration with companies in the field of mitochondrial biology and medicine such as Astellas, MitoAction and NAMDC, among others. Mitobridge is headquartered in Cambridge, Massachusetts, the US.

M3 Biotechnology Inc – Pharmaceuticals & Healthcare – market share and growth rate.  

 

HTF Market Intelligence released a new research report of 16 pages on title ‘M3 Biotechnology Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile’  with detailed analysis, forecast and strategies.

Summary

M3 Biotechnology Inc (M3 Biotech) is a therapeutics company with a focus on novel platform of pharmaceuticals that modifies growth-factor systems. The company provides therapies primarily for the treatment of neurodegenerative diseases. Its lead compound, MM-201, a therapeutic program, is an orally bioavailable small molecule mimetic of a neurotrophic factor. MM-201 focuses on central nervous system disorders such as Parkinson’s and Alzheimer’s disease. M3 Biotech also provides therapies for age related Dementia. The company utilizes a knowledge based discovery platform to identify novel small molecules and control protein growth factor multimerization in protein-protein interactions. M3 Biotech is headquartered in Seattle, Washington, the US.

Designed by CyFocus.com
Powered by CyFocus.net